GlobeNewsWire
12 Jun 2026, 00:00 UTC · 5h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Arcadia Biosciences is issuing approximately 3.88 million shares of common stock and associated preferred options in a $4 million private placement. — The issuance of millions of new shares creates immediate equity dilution for existing shareholders.
-0.40The company intends to use the net proceeds from the offering for working capital and general corporate purposes. — Using funds for general working capital rather than a specific growth catalyst often signals a need for liquidity to sustain operations.
-0.10The private placement was priced 'at-the-market' at $1.03 per share of common stock. — Pricing at the current market rate is neutral as it does not represent a significant premium or discount.
+0.00Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company is raising $4 million in capital for working capital and general corporate purposes, providing a liquidity boost.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
TheNewswire
4h ago
